GlassScriptPhysician profile
Yashmine Ballesteros
NPI 1942827985
$1,816.11
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $58.74 · 2023: $431 · 2024: $865 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.44 |
| Education | $298.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $221.03 | 2021 | |
| Daiichi Sankyo INC. | $185.53 | 2024 | Enhertu |
| Exelixis INC. | $154.03 | 2023-2024 | Cabometyx |
| Sobi, INC | $150.24 | 2024-2025 | |
| Incyte Corporation | $124.97 | 2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $122.06 | 2024 | Reblozyl |
| Janssen Biotech, INC. | $119.98 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $108.99 | 2022-2024 | Reblozyl |
| Astellas Pharma US INC | $99.95 | 2024 | |
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Karyopharm Therapeutics INC. | $66.57 | 2023-2024 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $60.14 | 2023 | Libtayo |
| Pfizer INC. | $57.31 | 2024 | |
| Genentech USA, INC. | $57.16 | 2022-2023 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $33.25 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $32.10 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Tactile Systems Technology INC | $24.44 | 2024 | Flexitouch Plus, Entre Plus |
| Rigel Pharmaceuticals, INC. | $19.73 | 2023 | Tavalisse, Rezlidhia |
| Emd Serono, INC. | $18.15 | 2024 | |
| Glaxosmithkline, LLC. | $17.43 | 2024 | Ojjaara |
| Blueprint Medicines Corporation | $16.60 | 2023 | Ayvakit |
| Seagen INC. | $13.76 | 2022 | |
| Abbvie INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yashmine Ballesteros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.